NCT06662526View on ClinicalTrials.gov

Lithium for Prevention of Cognitive Declining in Mood Illnesses

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2029

Study Completion Date

November 1, 2030

Conditions
DementiaBipolar Disorder (BD)Depression - Major Depressive DisorderMild Cognitive Impairment (MCI)
Interventions
DRUG

Trace lithium dose plus treatment as usual

Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years

DRUG

Placebo pill plus treatment as usual

Patients will receive a placebo pill plus treatment as usual by their clinical providers

Trial Locations (2)

8431621

Instituto Psiquiátrico Dr. José Horwitz Barak, Santiago

Psychiatric Institute Dr. José Horwitz Barak, Santiago

All Listed Sponsors
lead

University of Chile

OTHER

NCT06662526 - Lithium for Prevention of Cognitive Declining in Mood Illnesses | Biotech Hunter | Biotech Hunter